SCHEMBL609177

SCHEMBL609177

CNN(NC)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 3/20 0.41
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KCNN4 O15554 1/20 0.36
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CYP3A4 P08684 2/20 0.35
MAPT P10636 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
FAAH O00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9699580 0.77 KMT2A (0.52) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL677668 0.74 LMNA (0.46) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL11251562 0.72 ACHE (0.48) LMNAMEN1KMT2AHTTALDH1A1
SCHEMBL3658311 0.72 CHRM5 (0.52) LMNAMEN1KMT2ASMN1; SMN2TSHR
SCHEMBL27665984 0.72 L3MBTL1 (0.40) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL30496487 0.72 CYP2A6 (0.42) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL4552761 0.72 LMNA (0.45) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL4642647 0.72 L3MBTL1 (0.40) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7406305 0.72 ALDH1A1 (0.52) L3MBTL1MEN1KMT2ATSHRHTT
Benzene SCHEMBL22658153 0.71 ALDH1A1 (0.56) L3MBTL1LMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1153100-A1 PHOTOCHROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN POLYMERIC MATERIALS Great Lakes Chemical (Europe) GmbH (CH) 2001-11-14 EP claimed
WO-2000039245-A1 PHOTOCHROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN POLYMERIC MATERIALS GREAT LAKES CHEMICAL (EUROPE) GMBH (CH) 2000-07-06 WO claimed
CN-115611882-B Fluorescent compound and preparation method and application thereof 深圳大学 2024-07-09 CN disclosed
US-20170073359-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MOLECULAR PROBES, INC. 2017-03-16 US disclosed
WO-2017005412-A1 METHOD FOR SYNTHESISING ALIPHATIC AND AROMATIC AMIDES CLARIANT INTERNATIONAL LTD (CH) 2017-01-12 WO disclosed
US-20160139135-A1 Optically-Detectable Enzyme Substrates and Their Method of Use LIFE TECHNOLOGIES CORP (US) 2016-05-19 US disclosed
US-9039870-B2 Method for producing alkaline (meth)acrylamides CLARIANT FINANCE (BVI) LIMITED (VG) 2015-05-26 US disclosed
EP-2448914-B1 CONTINUOUS METHOD FOR PRODUCING AMIDES OF AROMATIC CARBOXYLIC ACIDS CLARIANT FINANCE BVI LTD (VG) 2014-11-26 EP disclosed
US-8884040-B2 Continuous method for producing fatty acid amides CLARIANT FINANCE (BVI) LIMITED (VG) 2014-11-11 US disclosed
US-8865891-B2 Optically-detectable enzyme substrates and their method of use Life Technologies Corporation (US) 2014-10-21 US disclosed
EP-2448915-B1 CONTINUOUS METHOD FOR PRODUCING AMIDES OF ALIPHATIC CARBOXYLIC ACIDS CLARIANT FINANCE BVI LTD (VG) 2013-12-04 EP disclosed
US-20090149652-A1 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES 2009-06-11 US disclosed
US-20090047692-A1 OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE INVITROGEN CORPORATION (US) 2009-02-19 US disclosed
WO-2008117175-A2 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2008-10-02 WO disclosed
US-7393861-B2 Derivatives of 4-aminopiperidine and their use as a medicament SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2008-07-01 US disclosed
WO-2008043492-A1 METHOD FOR PRODUCING ALKALINE (METH)ACRYLAMIDES CLARIANT FINANCE (BVI) LIMITED (VG) 2008-04-17 WO disclosed
US-20070060575-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2007-03-15 US disclosed
US-20050227309-A1 Optically-detectable enzyme substrates and their method of use MOLECULAR PROBES, INC. 2005-10-13 US disclosed
US-5506347-A ADENOSINE KINASE INHIBITOR GENSIA, INC. (US) 1996-04-09 US disclosed
US-5106716-A Polymer grains dispersed in non-aqueous solvent FUJI PHOTO FILM CO., LTD. (JP) 1992-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149652-A1 Derivatives of 4-aminopiperidine and their use as a medicament SSTR4, SSTR3, SSTR1 L3MBTL1 3893/4885LMNA 3780/4885MEN1 1998/4885
US-20070060575-A1 Aspartyl protease inhibitors CHRM2, BACE1, CHRM1 L3MBTL1 652/4885LMNA 1839/4885MEN1 1382/4885
US-20160139135-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MGAM, LCT, GAA L3MBTL1 443/4885LMNA 629/4885MEN1 3638/4885
US-20170073359-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MGAM, LCT, GAA L3MBTL1 443/4885LMNA 629/4885MEN1 3638/4885
US-20090047692-A1 OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE MGAM, LCT, GAA L3MBTL1 443/4885LMNA 629/4885MEN1 3638/4885
US-20050227309-A1 Optically-detectable enzyme substrates and their method of use MGAM, LCT, GAA L3MBTL1 443/4885LMNA 629/4885MEN1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.